Impact of Maternal Graves’ Disease on Neonatal Thyroid Function
Author Information
Author(s): Muacevic Alexander, Adler John R, Tzoraki Maria, Karampas Grigorios, Sarantaki Antigoni, Lykeridou Aikaterini, Kanaka-Gantenbein Christina, Metallinou Dimitra
Primary Institution: Hygeia Hospital, Aretaieio University Hospital, University of West Attica, Aghia Sophia Children's Hospital
Hypothesis
How does maternal Graves' disease affect neonatal thyroid outcomes?
Conclusion
Maternal Graves' disease significantly impacts neonatal thyroid function, with elevated TRAb levels being a strong predictor of dysfunction.
Supporting Evidence
- Elevated maternal TRAb levels are a strong predictor of neonatal thyroid dysfunction.
- The incidence of neonatal thyroid dysfunction ranges from 0.1% to 5% in pregnancies complicated by GD.
- Neonates often present with thyroid dysfunction early in life, but many show signs of resolution with treatment.
- Monitoring maternal TRAb levels in the third trimester is essential for assessing neonatal risk.
- Standardized protocols for monitoring and managing pregnancies complicated by GD are needed.
Takeaway
Moms with Graves' disease can pass on thyroid problems to their babies, so doctors need to check the babies' thyroids early.
Methodology
This systematic review included 18 studies examining neonatal thyroid function in relation to maternal Graves' disease.
Potential Biases
Most studies demonstrated a high risk of bias, particularly related to confounding and measurement issues.
Limitations
Many studies had small sample sizes and variability in treatment protocols, which may limit generalizability.
Participant Demographics
Neonates born to mothers with Graves' disease, with studies conducted across various countries.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website